QuinTron Instrument Company, Inc. recently secured a major technological breakthrough with the issuance of U.S. Patent No. 12721543. This patent, titled ‘Apparatus and methods for viral and bacterial breath collection’, introduces a powerful way to collect biological specimens. Medical professionals can now capture viruses and bacteria from human breath with the same precision previously reserved for invasive swabs. Invented by Eric L. Hamilton, this technology eliminates the need for uncomfortable sampling methods.
Advanced Detection for Viral Pathogens
The innovation focuses on a new breath collection design for medical testing systems. This system uses a specialized apparatus to process an exhaled breath specimen. A designated chamber within the device receives the breath flow. The breath is either passed directly through a capturing liquid or a specialized filter medium. A subsequent washing step ensures any trapped pathogens on the filter are effectively extracted into a liquid solution. This setup allows for incredible accuracy during laboratory testing and standard PCR analysis.
Wisconsin Patent of the Month Recognition
The invention won the patent of the month for the Wisconsin state for the month of October 2026 granted by Swanson Reed. QuinTron Instrument Company, Inc., located in Milwaukee, Wisconsin, earned this recognition due to the clinical significance and non-invasive nature of the technology. Providing an alternative to traditional nasal swabbing or blood draws improves patient compliance and testing accessibility. The technology represents a notable advancement in medical diagnostics that aligns closely with modern goals for enhancing public health testing infrastructure safely and efficiently.
Practical Applications and R&D Tax Credit Eligibility
The practical applications of this patent might be applied to be eligible for an R&D tax credit in the USA. Developing these collection systems requires extensive scientific testing and engineering to ensure that the filter media and liquids accurately trap microscopic viral and bacterial particles. Companies undertake significant technical risk when prototyping device iterations to optimize airflow dynamics, fluid interaction, and pathogen yield for clinical compatibility. The systematic evaluation of these design alternatives, material selection, and rigorous laboratory trials constitute qualified research activities. Consequently, expenses related to designing and testing such diagnostic devices can qualify for the federal Research and Development Tax Credit, financially rewarding companies for their medical innovation and technical problem solving.
